AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|
27.5 C
New York
Wednesday, July 1, 2026

Tag: programs

FHLBank San Francisco Awards $6.7 Million in Grants to Develop Affordable Housing in Arizona

Grants will add 204 units of affordable housing across Flagstaff, Pisinemo and Topawa, Prescott, and Tucson
Grants will add 204 units of affordable housing across Flagstaff, Pisinemo and Topawa, Prescott, and Tucson

NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Administration (“FDA”), to a patient with mild-stage Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. This exploratory work is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Chinola Fresh Fruit Liqueurs Expands Distribution with Southern Glazer’s Wine & Spirits Travel Retail Sales & Export Division

A strategic agreement poised to accelerate Chinola's global footprint across key export and travel retail markets. NEW YORK, July 10, 2025 /PRNewswire/ -- Chinola Fresh...

Make-A-Wish and ESPN team up for the 18th season of the “My Wish” series

Since 2006, the summer series has showcased more than 80 inspiring stories of wish kids meeting their favorite teams and athletes PHOENIX, July 10, 2025...

STAR OF THE SEAS OFFICIALLY JOINS ROYAL CARIBBEAN AS THE NEXT ICONIC VACATION

The ultimate family vacation has completed construction and is one step closer to its August debut in Port Canaveral (Orlando), Florida MIAMI, July 11, 2025...

STAR OF THE SEAS OFFICIALLY JOINS ROYAL CARIBBEAN AS THE NEXT ICONIC VACATION

The ultimate family vacation has completed construction and is one step closer to its August debut in Port Canaveral (Orlando), Florida MIAMI, July 10, 2025...

STAR OF THE SEAS OFFICIALLY JOINS ROYAL CARIBBEAN AS THE NEXT ICONIC VACATION

The ultimate family vacation has completed construction and is one step closer to its August debut in Port Canaveral (Orlando), Florida MIAMI, July 10, 2025...

STAR OF THE SEAS OFFICIALLY JOINS ROYAL CARIBBEAN AS THE NEXT ICONIC VACATION

The ultimate family vacation has completed construction and is one step closer to its August debut in Port Canaveral (Orlando), Florida MIAMI, July 10, 2025...

STAR OF THE SEAS OFFICIALLY JOINS ROYAL CARIBBEAN AS THE NEXT ICONIC VACATION

The ultimate family vacation has completed construction and is one step closer to its August debut in Port Canaveral (Orlando), Florida MIAMI, July 10, 2025...

FHLBank San Francisco Awards $5.1 Million in Grants for Affordable Housing in Nevada

FHLBank San Francisco Awards $5.1 Million in Grants for Affordable Housing in Nevada

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)

Important milestone towards public reimbursement for a new treatment option for eligible Canadian patients living with moderate to severe hidradenitis suppurativa (HS)Following this important...

His Royal Highness The Duke of Edinburgh Participates in Canadian Education Events Supporting Youth Development and Experiential Learning

CHARLOTTETOWN, PE and TORONTO, July 10, 2025 /CNW/ - As part of his broader visit to Canada, His Royal Highness The Duke of Edinburgh, participated in...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPrograms